Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEVISS: Y90 Ibritumomab Tiuxetan Post R-CHOP in Follicular Lymphoma
NCT01446562Phase 2Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- May 2007
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Sunnybrook Health Sciences Centre. Started May 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01446562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01446562.